[{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Neurology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Neurology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Neurology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Neurology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Horizon Health Network","sponsor":"London Health Sciences Centre Research Institute (Lawson) | University of Michigan | Jefferson Medical College of Thomas Jefferson University | McGill University | University of Western Ontario, Canada | Sanford Health | Carilion Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Neurology","graph2":"Phase IV","graph3":"Horizon Health Network","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Horizon Health Network \/ London Health Sciences Centre Research Institute (Lawson) | University of Michigan | Jefferson Medical College of Thomas Jefferson University | McGill University | University of Western Ontario, Canada | Sanford Health | Carilion Clinic","highestDevelopmentStatusID":"11","companyTruncated":"Horizon Health Network \/ London Health Sciences Centre Research Institute (Lawson) | University of Michigan | Jefferson Medical College of Thomas Jefferson University | McGill University | University of Western Ontario, Canada | Sanford Health | Carilion Clinic"},{"orgOrder":0,"company":"Sanford Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Sanford Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanford Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanford Health \/ Undisclosed"},{"orgOrder":0,"company":"Charleston Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Neurology","graph2":"Phase III","graph3":"Charleston Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Charleston Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Charleston Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Charleston Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Neurology","graph2":"Phase III","graph3":"Charleston Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Charleston Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Charleston Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Charleston Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Neurology","graph2":"Phase III","graph3":"Charleston Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Charleston Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Charleston Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Charleston Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Neurology","graph2":"Phase III","graph3":"Charleston Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Charleston Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Charleston Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Neurology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Neurology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"NEMA Research","sponsor":"Medtronic plc | International Clinical Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Neurology","graph2":"Phase IV","graph3":"NEMA Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NEMA Research \/ Medtronic plc | International Clinical Research Institute","highestDevelopmentStatusID":"11","companyTruncated":"NEMA Research \/ Medtronic plc | International Clinical Research Institute"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Charleston Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Undisclosed","graph2":"Phase I","graph3":"Charleston Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charleston Laboratories \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Charleston Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Joseph Hazelton","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Neurology","graph2":"Phase III","graph3":"Joseph Hazelton","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Joseph Hazelton \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Joseph Hazelton \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharma Advanced Research Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Undisclosed","graph2":"Phase I","graph3":"Sun Pharma Advanced Research Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Pharma Advanced Research Company \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sun Pharma Advanced Research Company \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Neurology","graph2":"Phase I","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Neurology","graph2":"Phase I","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Quivive Pharma","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Undisclosed","graph2":"Phase I","graph3":"Quivive Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Quivive Pharma \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"Quivive Pharma \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Zogenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Neurology","graph2":"Phase III","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zogenix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zogenix \/ Undisclosed"},{"orgOrder":0,"company":"Zogenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Neurology","graph2":"Phase III","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zogenix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zogenix \/ Undisclosed"},{"orgOrder":0,"company":"Zogenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Zogenix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zogenix \/ Undisclosed"},{"orgOrder":0,"company":"CEPHALON INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"CEPHALON INC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Powder","sponsorNew":"CEPHALON INC \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CEPHALON INC \/ Undisclosed"},{"orgOrder":0,"company":"Purdue Pharmaceuticals L.P","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Neurology","graph2":"Phase II","graph3":"Purdue Pharmaceuticals L.P","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Purdue Pharmaceuticals L.P \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Purdue Pharmaceuticals L.P \/ Undisclosed"},{"orgOrder":0,"company":"CEPHALON INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Nephrology","graph2":"Phase I","graph3":"CEPHALON INC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CEPHALON INC \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CEPHALON INC \/ Undisclosed"},{"orgOrder":0,"company":"CEPHALON INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"CEPHALON INC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CEPHALON INC \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CEPHALON INC \/ Undisclosed"},{"orgOrder":0,"company":"Zogenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Neurology","graph2":"Phase II","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Zogenix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zogenix \/ Undisclosed"},{"orgOrder":0,"company":"Purdue Pharmaceuticals L.P","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Neurology","graph2":"Phase III","graph3":"Purdue Pharmaceuticals L.P","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Purdue Pharmaceuticals L.P \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Purdue Pharmaceuticals L.P \/ Undisclosed"},{"orgOrder":0,"company":"Purdue Pharmaceuticals L.P","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Neurology","graph2":"Phase III","graph3":"Purdue Pharmaceuticals L.P","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Purdue Pharmaceuticals L.P \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Purdue Pharmaceuticals L.P \/ Undisclosed"},{"orgOrder":0,"company":"Acura Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"||Opioid receptors; mu\/kappa\/delta","graph1":"Neurology","graph2":"Phase III","graph3":"Acura Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Acura Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acura Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Acura Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"||Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Acura Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Acura Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Acura Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Acura Pharmaceuticals","sponsor":"Abuse Deterrent Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Hydrocodone Bitartrate","moa":"||Opioid receptors; mu\/kappa\/delta","graph1":"Neurology","graph2":"Phase III","graph3":"Acura Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Acura Pharmaceuticals \/ Abuse Deterrent Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Acura Pharmaceuticals \/ Abuse Deterrent Pharmaceuticals"},{"orgOrder":0,"company":"Acura Pharmaceuticals","sponsor":"Abuse Deterrent Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Hydrocodone Bitartrate","moa":"||Opioid receptors; mu\/kappa\/delta","graph1":"Neurology","graph2":"Phase III","graph3":"Acura Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Acura Pharmaceuticals \/ Abuse Deterrent Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Acura Pharmaceuticals \/ Abuse Deterrent Pharmaceuticals"},{"orgOrder":0,"company":"Acura Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"||Opioid receptors; mu\/kappa\/delta","graph1":"Neurology","graph2":"Phase III","graph3":"Acura Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Acura Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acura Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zogenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zogenix \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zogenix \/ Undisclosed"},{"orgOrder":0,"company":"Zogenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Nephrology","graph2":"Phase I","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zogenix \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zogenix \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals for Hydrocodone
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
